stella
beta
Improved Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Protocol for the Treatment of Epstein Barr Virus T/NK Lymphoproliferative Disease (EBV-T/NK LPD) and Prevention of Post Transplant Graft-versus-host Disease — Stella
Recruiting
Back to EBV-T/NK LPD trials
Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.
Trial locations
(1 site)
China
Beijing Children's Hospital Capital Medical University, Beijing
View full record on ClinicalTrials.gov